Neurological complication during pregnancy, delivery and puerperium requiring intensive therapy management

Neurological complications during pregnancy, delivery and puerperium are relatively rare, but can lead to serious consequences and life-threatening situations. Clinical symptoms such as headache, weakness, seizures, sudden neurological deficits, or decreased level of consciousness should be the reasons for a prompt and careful consideration and neuroimaging to confirm the diagnosis and initiate treatment. In this article, we aim to describe the diseases and clinical situations that may manifest as neurological symptoms during pregnancy, delivery and puerperium. We also provide a more comprehensive descriptions of certain pregnancy-specific diseases and latest findings in literature and improvement in diagnostic approaches and treatment. Our primary objective is to emphasise the urgent need for prompt and accurate diagnosis and treatment in order to prevent life-threatening situations, not only for the mother, but also for the baby.

Pregnancy; Neurological complication; Headache; Seizures; Stroke; Preeclampsia; Eclampsia; Posterior reversible encephalopathy syndrome; Reversible cerebral vasoconstriction syndrome; Cerebral venous thrombosis

[1] Goldszmidt E, Kern R, Chaput A, Macarthur A. The incidence and etiology of postpartum headaches: a prospective cohort study. Canadian Journal of Anesthesia. 2005; 52: 971–977.

[2] Janvier AS, Russell R. Postpartum headache—diagnosis and treatment. BJA Education. 2022; 22: 176–181.

[3] Camargo EC, Singhal AB. Stroke in pregnancy: a multidisciplinary approach. Obstetrics and Gynecology Clinics of North America. 2021; 48: 75–96.

[4] Bourgioti C, Konidari M, Gourtsoyianni S, Moulopoulos LA. Imaging during pregnancy: what the radiologist needs to know. Diagnostic and Interventional Imaging. 2021; 102: 593–603.

[5] Kazma JM, van den Anker J, Allegaert K, Dallmann A, Ahmadzia HK. Anatomical and physiological alterations of pregnancy. Journal of Pharmacokinetics and Pharmacodynamics. 2020; 47: 271–285.

[6] Kearsley R, Stocks G. Venous thromboembolism in pregnancy—diagnosis, management, and treatment. BJA Education. 2021; 21: 117–123.

[7] Malaiyandi D, James E, Peglar L, Karim N, Henkel N, Guilliams K. Neurocritical care of the pregnant patient. Current Treatment Options in Neurology. 2021; 23: 22.

[8] Johnson AC, Cipolla MJ. The cerebral circulation during pregnancy: adapting to preserve normalcy. Physiology. 2015; 30: 139–147.

[9] Bergman L, Cluver C, Carlberg N, Belfort M, Tolcher MC, Panerai RB, et al. Cerebral perfusion pressure and autoregulation in eclampsia—a case control study. American Journal of Obstetrics and Gynecology. 2021; 225: 185.e1–185.e9.

[10] Friis T, Wikström AK, Acurio J, León J, Zetterberg H, Blennow K, et al. Cerebral biomarkers and blood-brain barrier integrity in preeclampsia. Cells. 2022; 11: 789.

[11] Mazzone PP, Hogg KM, Weir CJ, Stephen J, Bhattacharya S, Chin RFM. Comparison of perinatal outcomes for women with and without epilepsy: a systematic review and meta-analysis. JAMA Neurology. 2023; 80: 484–494.

[12] Gyamfi-Bannerman C, Huang Y, Bateman BT, Benson RJ, Pack AM, Wright JD, et al. Maternal morbidity and mortality associated with epilepsy. The Journal of Maternal-Fetal & Neonatal Medicine. 2022; 35: 7917–7923.

[13] MacDonald SC, Bateman BT, McElrath TF, Hernández-Díaz S. Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States. JAMA Neurology. 2015; 72: 981–988.

[14] Van Marter LJ, Pennell PB, Brown C, Hartman AL, May RC, McElrath T, et al. Neonatal outcomes in the MONEAD study of pregnant women with epilepsy. The Journal of Pediatrics: X. 2021; 7: 100073.

[15] Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research. 2008; 81: 1–13.

[16] Avachat C, Barry JM, Lyu X, Sherwin CM, Birnbaum AK. Management of anti-seizure medications during pregnancy: advancements in the past decade. Pharmaceutics. 2022; 14: 2733.

[17] Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009; 73: 126–132.

[18] Yerby M, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia. 1985; 26: 631–635.

[19] Coppler PJ, Elmer J. Status epilepticus: a neurologic emergency. Critical Care Clinics. 2023; 39: 87–102.

[20] Roberti R, Rocca M, Iannone LF, Gasparini S, Pascarella A, Neri S, et al. Status epilepticus in pregnancy: a literature review and a protocol proposal. Expert Review of Neurotherapeutics. 2022; 22: 301–312.

[21] Dimitriadis E, Rolnik DL, Zhou W, Estrada-Gutierrez G, Koga K, Francisco RPV, et al. Pre-eclampsia. Nature reviews. Disease Primers. 2023; 9: 8.

[22] Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, et al. Preeclampsia, eclampsia, and adverse maternal and perinatal outcomes: a secondary analysis of the world health organization multicountry survey on maternal and newborn health. Obstetric Anesthesia Digest. 2015; 35: 20–21.

[23] Laskowska M. Eclampsia: a critical pregnancy complication demanding enhanced maternal care: a review. Medical Science Monitor. 2023; 29: e939919.

[24] Tanner MS, Davey M, Mol BW, Rolnik DL. The evolution of the diagnostic criteria of preeclampsia-eclampsia. American Journal of Obstetrics and Gynecology. 2022; 226: S835–S843.

[25] Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 international society for the study of hypertension in pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertension. 2022; 27: 148–169.

[26] Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019; 366: l2381.

[27] Martínez-Martínez MM, Fernández-Travieso J, Gómez Muñoz N, Varela Mezquita B, Almarcha-Menargues ML, Miralles Martínez A. Cerebral hemodynamics and vasoconstriction in preeclampsia: from diagnosis to resolution. Pregnancy Hypertension. 2021; 26: 42–47.

[28] Pratt JJ, Niedle PS, Vogel JP, Oladapo OT, Bohren M, Tunçalp Ö, et al. Alternative regimens of magnesium sulfate for treatment of preeclampsia and eclampsia: a systematic review of non-randomized studies. Acta Obstetricia Et Gynecologica Scandinavica. 2016; 95: 144–156.

[29] Zuspan FP. Problems encountered in the treatment of pregnancy-induced hypertension. A point of view. American Journal of Obstetrics and Gynecology. 1978; 131: 591–597.

[30] Lam MC, Dierking E. Intensive Care Unit issues in eclampsia and HELLP syndrome. International Journal of Critical Illness and Injury Science. 2017; 7: 136–141.

[31] Pollock W, Rose L, Dennis C. Pregnant and postpartum admissions to the intensive care unit: a systematic review. Intensive Care Medicine. 2010; 36: 1465–1474.

[32] Patel R, Urits I, Orhurhu V, Orhurhu MS, Peck J, Ohuabunwa E, et al. A comprehensive update on the treatment and management of postdural puncture headache. Current Pain and Headache Reports. 2020; 24: 24.

[33] Song TJ, Lee KH, Li H, Kim JY, Chang K, Kim SH, et al. Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review. European Review for Medical and Pharmacological Sciences. 2021; 25: 3519–3529.

[34] Ljubisavljevic S. Postdural puncture headache as a complication of lumbar puncture: clinical manifestations, pathophysiology, and treatment. Neurological Sciences. 2020; 41: 3563–3568.

[35] Shin HY. Recent update on epidural blood patch. Anesthesia and Pain Medicine. 2022; 17: 12–23.

[36] Basurto Ona X, Osorio D, Bonfill Cosp X. Drug therapy for treating post-dural puncture headache. Cochrane Database of Systematic Reviews. 2015; 2015: CD007887.

[37] Elgendy IY, Bukhari S, Barakat AF, Pepine CJ, Lindley KJ, Miller EC. Maternal stroke: a call for action. Circulation. 2021; 143: 727–738.

[38] Kremer C, Gdovinova Z, Bejot Y, Heldner MR, Zuurbier S, Walter S, et al. European stroke organisation guidelines on stroke in women: Management of menopause, pregnancy and postpartum. European Stroke Journal. 2022; 7: I–XIX.

[39] Ascanio LC, Maragkos GA, Young BC, Boone MD, Kasper EM. Spontaneous intracranial hemorrhage in pregnancy: a systematic review of the literature. Neurocritical Care. 2019; 30: 5–15.

[40] Wiącek M, Oboz-Adaś A, Kuźniar K, Karaś A, Jasielski P, Bartosik-Psujek H. Acute ischemic stroke in pregnancy: a practical focus on neuroimaging and reperfusion therapy. Clinical Neuroradiology. 2023; 33: 31–39.

[41] Ladhani NNN, Swartz RH, Foley N, Nerenberg K, Smith EE, Gubitz G, et al. Canadian stroke best practice consensus statement: acute stroke management during pregnancy. International Journal of Stroke. 2018; 13: 743–758.

[42] Dicpinigaitis AJ, Sursal T, Morse CA, Briskin C, Dakay K, Kurian C, et al. Endovascular thrombectomy for treatment of acute ischemic stroke during pregnancy and the early postpartum period. Stroke. 2021; 52: 3796–3804.

[43] Brewer J, Owens MY, Wallace K, Reeves AA, Morris R, Khan M, et al. Posterior reversible encephalopathy syndrome in 46 of 47 patients with eclampsia. American Journal of Obstetrics and Gynecology. 2013; 208: 468.e1–468.e6.

[44] Cheng X, Li J, Lan Y, Liu J, Chen S, Lu G. Cerebrovascular disease in the setting of posterior reversible encephalopathy syndrome. Frontiers in neurology. 2021; 12: 765333.

[45] Bahadur A, Mundhra R, Singh R, Mishra J, Suresh G, Jaiswal S, et al. Predictors of posterior reversible encephalopathy syndrome (PRES) in women with pre-eclampsia/eclampsia: a retrospective analysis. Cureus. 2022; 14: e31459.

[46] Triplett JD, Kutlubaev MA, Kermode AG, Hardy T. Posterior reversible encephalopathy syndrome (PRES): diagnosis and management. Practical Neurology. 2022; 22: 183–189

[47] Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. The New England Journal of Medicine. 1996; 334: 494–500.

[48] Ismail FS, van de Nes J, Kleffner I. A broad spectrum of posterior reversible encephalopathy syndrome—a case series with clinical and paraclinical characterisation, and histopathological findings. BMC Neurology. 2021; 21: 386.

[49] McKinney AM, Sarikaya B, Gustafson C, Truwit CL. Detection of microhemorrhage in posterior reversible encephalopathy syndrome using susceptibility-weighted imaging. American Journal of Neuroradiology. 2012; 33: 896–903.

[50] Mahendra V, Clark SL, Suresh MS. Neuropathophysiology of preeclampsia and eclampsia: a review of cerebral hemodynamic principles in hypertensive disorders of pregnancy. Pregnancy Hypertension. 2021; 23: 104–111.

[51] Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. The Lancet Neurology. 2015; 14: 914–925.

[52] Singh S, Mohakud S, Naik S, Jena SK, Sethi P, Nayak P. Predictors of posterior reversible encephalopathy syndrome in women with hypertension in pregnancy: a prospective observational study. Pregnancy Hypertension. 2021; 23: 191–195.

[53] Chen Z, Zhang G, Lerner A, Wang A, Gao B, Liu J. Risk factors for poor outcome in posterior reversible encephalopathy syndrome: systematic review and meta-analysis. Quantitative Imaging in Medicine and Surgery. 2018; 8: 421–432.

[54] Shaikh N, Nawaz S, Ummunisa F, Shahzad A, Hussain J, Ahmad K, et al. Eclampsia and posterior reversible encephalopathy syndrome (PRES): a retrospective review of risk factors and outcomes. Qatar Medical Journal. 2021; 2021: 4.

[55] Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. Journal of Hypertension. 2018; 36: 1953–2041.

[56] Servillo G, Bifulco F, De Robertis E, Piazza O, Striano P, Tortora F, et al. Posterior reversible encephalopathy syndrome in intensive care medicine. Intensive Care Medicine. 2007; 33: 230–236.

[57] Skeik N, Porten BR, Kadkhodayan Y, McDonald W, Lahham F. Postpartum reversible cerebral vasoconstriction syndrome: review and analysis of the current data. Vascular Medicine. 2015; 20: 256–265.

[58] Gewirtz AN, Gao V, Parauda SC, Robbins MS. Posterior reversible encephalopathy syndrome. Current Pain and Headache Reports. 2021; 25: 19.

[59] Ribas MZ, Paticcié GF, de Medeiros SDP, de Oliveira Veras A, Noleto FM, dos Santos JCC. Reversible cerebral vasoconstriction syndrome: literature review. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2023; 59: 5.

[60] Peace JM, Bhat AD, Peralta FM. Anesthetic management of reversible cerebral vasoconstriction syndrome during vaginal delivery: a case report. A&A Practice. 2020; 14: e01298.

[61] Burton TM, Bushnell CD. Reversible cerebral vasoconstriction syndrome. Stroke. 2019; 50: 2253–2258.

[62] de Boysson H, Parienti J, Mawet J, Arquizan C, Boulouis G, Burcin C, et al. Primary angiitis of the CNS and reversible cerebral vasoconstriction syndrome. Neurology. 2018; 91: e1468–e1478.

[63] McIlroy E, Sethuraman R, Woograsingh R, Nelson-Piercy C, Gilbert-Kawai E. Severe postpartum headache and hypertension caused by reversible cerebral vasoconstriction syndrome. A&A Case Reports. 2017; 9: 289–291.

[64] Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible cerebral vasoconstriction syndrome, part 1: epidemiology, pathogenesis, and clinical course. American Journal of Neuroradiology. 2015; 36: 1392–1399.

[65] Choi HA, Lee MJ, Chung C. Cerebral endothelial dysfunction in reversible cerebral vasoconstriction syndrome: a case-control study. The Journal of Headache and Pain. 2017; 18: 29.

[66] Chen SP, Wang SJ. Pathophysiology of reversible cerebral vasoconstriction syndrome. Journal of Biomedical Science. 2022; 29: 72.

[67] Bernard KRL, Rivera M. Reversible cerebral vasoconstriction syndrome. The Journal of Emergency Medicine. 2015; 49: 26–31.

[68] Aguiar de Sousa D. Cerebral venous thrombosis: what’s new? HäMostaseologie. 2021; 41: 25–30.

[69] Ferro JM, Canhão P, Stam J, Bousser M, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis (ISCVT). Stroke. 2004; 35: 664–670.

[70] Soleau SW, Schmidt R, Stevens S, Osborn A, MacDonald JD. Extensive experience with dural sinus thrombosis. Neurosurgery. 2003; 52: 534–544.

[71] Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone S, Maier S, et al. Postpartum cerebral venous thrombosis—a single-center experience. Brain Sciences. 2021; 11: 327.

[72] Baldini T, Asioli GM, Romoli M, Carvalho Dias M, Schulte EC, Hauer L, et al. Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis. European Journal of Neurology. 2021; 28: 3478–3490.

[73] Silvis SM, Lindgren E, Hiltunen S, Devasagayam S, Scheres LJ, Jood K, et al. Postpartum period is a risk factor for cerebral venous thrombosis. Stroke. 2019; 50: 501–503.

[74] Kashkoush AI, Ma H, Agarwal N, Panczykowski D, Tonetti D, Weiner GM, et al. Cerebral venous sinus thrombosis in pregnancy and puerperium: a pooled, systematic review. Journal of Clinical Neuroscience. 2017; 39: 9–15.

[75] Idiculla PS, Gurala D, Palanisamy M, Vijayakumar R, Dhandapani S, Nagarajan E. Cerebral venous thrombosis: a comprehensive review. European Neurology. 2020; 83: 369–379.

[76] Alimohammadi A, Kim DJ, Field TS. Updates in cerebral venous thrombosis. Current Cardiology Reports. 2022; 24: 43–50.

[77] Goyal M, Fladt J, Coutinho JM, McDonough R, Ospel J. Endovascular treatment for cerebral venous thrombosis: current status, challenges, and opportunities. Journal of NeuroInterventional Surgery. 2022; 14: 788–793.

[78] Ferro JM, Bousser MG, Canhão P, Coutinho JM, Crassard I, Dentali F, et al. European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European academy of neurology. European Journal of Neurology. 2017; 24: 1203–1213.

[79] Coutinho JM, van den Berg R, Zuurbier SM, VanBavel E, Troost D, Majoie CB, et al. Small juxtacortical hemorrhages in cerebral venous thrombosis. Annals of Neurology. 2014; 75: 908–916.

[80] Schaller B, Graf R. Cerebral venous infarction: the pathophysiological concept. Cerebrovascular Diseases. 2004; 18: 179–188.

[81] León-García M, Humphries B, Maraboto A, Rabassa M, Boehmer KR, Perestelo-Perez L, et al. Women’s values and preferences on low-molecular-weight heparin and pregnancy: a mixed-methods systematic review. BMC Pregnancy and Childbirth. 2022; 22: 747.

[82] Durmuș B, Yperzeele L, Zuurbier SM. Cerebral venous thrombosis in women of childbearing age: diagnosis, treatment, and prophylaxis during a future pregnancy. Therapeutic Advances in Neurological Disorders. 2020; 13: 1756286420945169.

[83] Bistervels IM, Buchmüller A, Wiegers HMG, Ní Áinle F, Tardy B, Donnelly J, et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (highlow study): an open-label, multicentre, randomised, controlled trial. The Lancet. 2022; 400: 1777–1787.

[84] Enakpene CA, Pontarelli KN, Della Torre M. Comparison of continuation of low-molecular-weight heparin versus switching to unfractionated heparin in the peripartum. American Journal of Perinatology. 2020; 37: 304–312.

[85] Coutinho JM, Zuurbier SM, Bousser M, Ji X, Canhão P, Roos YB, et al. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial. JAMA Neurology. 2020; 77: 966–973.

[86] Hiltunen S, Putaala J, Haapaniemi E, Tatlisumak T. Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients. Journal of Neurology. 2016; 263: 477–484.

[87] Kareemi H, Pratte M, English S, Hendin A. Initial diagnosis and management of acutely elevated intracranial pressure. Journal of Intensive Care Medicine. 2023; 38: 643–650.

[88] Godoy DA, Robba C, Paiva WS, Rabinstein AA. Acute Intracranial hypertension during pregnancy: special considerations and management adjustments. Neurocritical Care. 2022; 36: 302–316.

[89] Shin J. Anesthetic management of the pregnant patient: part 2. Anesthesia Progress. 2021; 68: 119–127.

[90] Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. Journal of the American College of Cardiology. 2019; 73: 457–476.

[91] Biricik E, Ünlügenç H. Vasopressors for the treatment and prophylaxis of spinal induced hypotension during caesarean section. Turkish Journal of Anaesthesiology and Reanimation. 2021; 49: 3–10.

[92] Ratnani I, Ochani RK, Shaikh A, Jatoi HN. Vasoplegia: a review. Methodist DeBakey Cardiovascular Journal. 2023; 19: 38–47.

[93] Ducrocq N, Kimmoun A, Furmaniuk A, Hekalo Z, Maskali F, Poussier S, et al. Comparison of equipressor doses of norepinephrine, epinephrine, and phenylephrine on septic myocardial dysfunction. Anesthesiology. 2012; 116: 1083–1091.

[94] Ngan Kee WD, Lee SWY, Ng FF, Tan PE, Khaw KS. Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery. Anesthesiology. 2015; 122: 736–745.

[95] Wang T, Liao L, Tang X, Li B, Huang S. Effects of different vasopressors on the contraction of the superior mesenteric artery and uterine artery in rats during late pregnancy. BMC Anesthesiology. 2021; 21: 185.

[96] Schizodimos T, Soulountsi V, Iasonidou C, Kapravelos N. An overview of management of intracranial hypertension in the intensive care unit. Journal of Anesthesia. 2020; 34: 741–757.

[97] Alali AS, Temkin N, Barber J, Pridgeon J, Chaddock K, Dikmen S, et al. A clinical decision rule to predict intracranial hypertension in severe traumatic brain injury. Journal of Neurosurgery. 2019; 131: 612–619.

[98] Robba C, Graziano F, Guglielmi A, Rebora P, Galimberti S, Taccone FS, et al. Treatments for intracranial hypertension in acute brain-injured patients: grading, timing, and association with outcome. Data from the SYNAPSE-ICU study. Intensive Care Medicine. 2023; 49: 50–61.

[99] Godoy DA, Brasil S, Iaccarino C, Paiva W, Rubiano AM. The intracranial compartmental syndrome: a proposed model for acute brain injury monitoring and management. Critical Care. 2023; 27: 137.

[100] Basso A, Fernández A, Althabe O, Sabini G, Piriz H, Belitzky R. Passage of mannitol from mother to amniotic fluid and fetus. Obstetrics and Gynecology. 1977; 49: 628–631.

[101] Pandey SK, Dass D. Drugs of physical harm in pregnancy: nature vs. nurture—a silent battle. Journal of Applied Pharmaceutical Science. 2012; 2: 11–19.